Abstract
It is important to assess drug abuse liability in real life by post-marketing surveillance system. In France, to obtain information on drug abuse liability, the Centers for Evaluation and Information on Pharmacodependence (CEIP) network was created in 1990 with the following aims: detection, prevention, evaluation, and information on drug abuse liability. Its specific work is based on a global, scientific assessment involving preclinical data, clinical studies, and post-marketing surveillance. This network has developed several pharmaco-epidemiological approaches to improve knowledge of drug use in real-life. The aim of this article was to describe a French post-marketing surveillance called OPPIDUM (Observation des Produits Psychotropes Illicites ou Détournés de leur Utilisation Médicamenteuse, Observation of Illegal Drugs and Misuse of Psychotropic Medications). OPPIDUM is an annual cross-sectional survey that collects anonymous information on abuse and dependence observed in patients recruited by specialized care centers dedicated to drug dependence. For each patient included sociodemographic data and psychoactive substance consumptions during the previous week were collected. From 1990 to 2010, a total of 50,734 patients were included with descriptions of 102,631 psychoactive substances. This OPPIDUM data has outlined emergent behaviors, such as use of high dosage buprenorphine by intravenous administration. It has contributed to characterize patients under opiate maintenance treatments and to assess abuse liability of emergent drugs as clonazepam. This pharmacoepidemiologic tool has also detected the decrease of flunitrazepam abuse following implementation of regulatory measures. OPPIDUM’s experience clearly demonstrates that collection of valid and useful data on drug abuse is possible. This post-marketing surveillance system offers important and useful information for physicians and health authorities.

This publication has 25 references indexed in Scilit: